Fox Christine
- SEC CIK
- 0001998173
In the past year, 5 open-market sale filings worth $2.75M and no purchases.
Current role at each company
- TEVA Teva Pharmaceutical Industries LtdEVP, U.S. Commercialas of May 4, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $2.75M
- 5 filings
- Net
- −$2.75M
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Fox Christine as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 (view filing) | Apr 30 | 4 days | Fox ChristineEVP, U.S. Commercial | SSale | −21.3K | $35.31 | −$750.6K | −25.0%63.6K after | |
| Mar 9, 2026 (view filing) | Mar 5 | 4 days | Fox ChristineEVP, U.S. Commercial | SSale | −7.92K | $31.67 | −$251.0K | −8.5%84.9K after | 10b5-1 |
| Mar 6, 2026 (view filing) | Mar 4 | 2 days | Fox ChristineEVP, U.S. Commercial | SSale | −9.10K | $32.46 | −$295.3K | −10.8%75.0K after | 10b5-1 |
| Nov 24, 2025 (view filing) | Nov 20 | 4 days | Fox ChristineEVP, Head of U.S. Commercial | SSale | −28.2K | $24.78 | −$699.5K | −30.7%63.6K after | 10b5-1 |
| Nov 18, 2025 (view filing) | Nov 14 | 4 days | Fox ChristineEVP, Head of U.S. Commercial | SSale | −30.0K | $25.11 | −$753.3K | −51.4%28.4K after | |
| Mar 6, 2025 (view filing) | Mar 4-5 | 2 days | Fox ChristineEVP, Head of U.S. Commercial | SSale | −6.18K | $15.79 | −$97.6K | −9.6%58.4K after | 2 lots10b5-1 |
| Nov 21, 2024 (view filing) | Nov 20 | 1 day | Fox ChristineEVP, Head of U.S. Commercial | SSale | −19.4K | $16.87 | −$327.1K | −30.5%44.1K after | 10b5-1 |